Prix Galien USA Names HUMIRA Best Biotechnology Product
- Details
- Category: Abbott
Abbott (NYSE: ABT), a leader in the treatment of autoimmune diseases, has received the 2007 Galen Prize for Best Biotechnology Product for HUMIRA (R) (adalimumab), the first approved fully human antibody. HUMIRA is approved for use in the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and moderate to severe Crohn's disease.
Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, and Genzyme Corporation, USA, today announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis (MS).
Anti-Tumor Activity of Single-Agent Sunitinib Malate in Advanced Gastric Cancer
- Details
- Category: Pfizer
Preliminary results from a new Phase II study provide data on the anti-tumor activity and tolerability of sunitinib malate in patients with advanced gastric cancer. Additionally, data from phase I studies provide information on the tolerability and safety of sunitinib malate in combination with current standard of care chemotherapies in the treatment of hormone-refractory prostate cancer (HRPC) and advanced breast cancer.
Start of the TALENT Study - a Unique Antihypertensive Study in Europe
- Details
- Category: Bayer
Bayer Schering Pharma AG announces the kick-start of the TALENT study, a multicenter "STudy EvALuating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control", which will examine two of its major antihypertensive brands in combination with each other.
Nycomed and NPS Pharmaceuticals Announce Licensing Agreement for GATTEX™
- Details
- Category: Nycomed
Nycomed and NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced that they have entered into a definitive agreement which licenses to Nycomed the rights to develop and commercialize GATTEX™ (teduglutide) outside the United States, Canada and Mexico for the treatment of gastrointestinal disorders.
FDA Accepts sNDA for Expanded Use of Angiomax®
- Details
- Category: Product
The Medicines Company (NASDAQ: MDCO) announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's supplemental new drug application (sNDA) for a modified dosing regimen of Angiomax® (bivalirudin) for the treatment of acute coronary syndromes (ACS), specifically in patients with unstable angina or non-segment elevation myocardial infarction (NSTEMI).
Protherics licenses its Covaccine HT adjuvant to Nobilon for influenza vaccine indications
- Details
- Category: Product
Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, and Nobilon International B.V., part of Organon, the human health care business unit of Akzo Nobel, today announced that Nobilon has licensed Protherics' CoVaccine HT™ adjuvant for use in pandemic influenza vaccines and seasonal influenza vaccines in elderly people.
More Pharma News ...
- Bristol-Myers Squibb to Acquire Adnexus Therapeutics
- Protherics signs ReGel⢠licensing agreement with Myungmoon Pharm
- Lundbeck in-licenses Circadin®, a drug approved for the treatment of primary insomnia
- First in a New Oral Class of HIV Medicines in 10 Years
- Sanofi-aventis Enters the Dow Jones Sustainability World Indexes
- Tasigna® recommended for European approval to treat rare form of leukemia
- European licence for Roche HIV drug Viracept recommended for re-instatement